Detection of Etomidate and Etomidate Acid in Urine Using HPLC-MS/MS Method

doi:10.12116/j.issn.1004-5619.2023.330702

Abstract

Abstract:

Objective To establish a high performance liquid chromatography-tandem mass spectrometry （HPLC-MS/MS） method for the detection of etomidate and etomidate acid in urine samples. Methods Protein in the urine samples was precipitated by adding acetonitrile, and the supernatant was obtained after centrifugation and filtered. The supernatant was separated on a C₁₈ column with a mobile phase consisting of 0.1% formic acid solution and acetonitrile at a flow rate of 0.4 mL/min. The detection was performed in positive electrospray ionization （ESI） and multiple reaction monitoring （MRM） modes. The method was validated for selectivity, linearity and limit of detection （LOD）, and applied to a case of etomidate poisoning death. Results The LOD of etomidate and etomidate acid were 0.2 and 0.5 ng/mL, respectively, and the limit of quantitation （LOQ） were 0.5 and 1.0 ng/mL, respectively. Good linear relationship was observed within the linear range （r>0.995 0）. At three concentration levels （0.5, 5, 50 ng/mL for etomidate and 1, 10, 100 ng/mL for etomidate acid）, the matrix effect was within the range of 5.42% to 18.47%, the extraction recovery rate was greater than 84.25% and the stability was greater than 88.23%. The accuracy, precision and dilution reliability all met the experimental requirements. Etomidate and etomidate acid were successfully detected with the concentrations of 8.82 and 27.88 μg/mL in the urine of a deceased individual who had consumed excessive etomidate. Conclusion The method has simple pretreatment, high sensitivity and wide linear range, which can be applied to the detection of etomidate and etomidate acid in urine samples in forensic science.

Key words: forensic medicine, toxicological analysis, etomidate, etomidate acid, high performance liquid chromatography-tandem mass spectrometry （HPLC-MS/MS）, urine

CLC Number:

Tian-fu HE, Huan-hui ZHU, Yuan-yuan TIAN, Yin-shuang JIN, Xian-wen LIN, Song-cai WANG. Detection of Etomidate and Etomidate Acid in Urine Using HPLC-MS/MS Method[J]. Journal of Forensic Medicine, 2024, 40(5): 454-460.

Add to citation manager EndNote|Ris|BibTeX

URL: http://www.fyxzz.cn/EN/10.12116/j.issn.1004-5619.2023.330702

http://www.fyxzz.cn/EN/Y2024/V40/I5/454

Figures/Tables 9

References 18

1	GODEFROI E F， JANSSEN P A， VANDEREYCKEN C A， et al. Dl-1-（1-arylalkyl）imidazole-5-carboxylate esters. A novel type of hypnotic agents[J]. J Med Chem，1965，8：220-223. doi：10.1021/jm00326a017 .
2	ATUCHA E， HAMMERSCHMIDT F， ZOLLE I， et al. Structure-activity relationship of etomidate derivatives at the GABA（A） receptor： Comparison with binding to 11beta-hydroxylase[J]. Bioorg Med Chem Lett，2009，19（15）：4284-4287. doi：10.1016/j.bmcl.2009.05.065 .
3	EBERT T J， MUZI M， BERENS R， et al. Sympathetic responses to induction of anesthesia in humans with propofol or etomidate[J]. Anesthesiology，1992，76（5）：725-733. doi：10.1097/00000542-199205000-00010 .
4	SMĘDRA A， WOCHNA K， KAŹMIERSKI D， et al. Suicide committed by a paramedic using a cocktail of drugs： Morphine， etomidate， diazepam and rocuronium. Case report and review of literature[J]. Leg Med （Tokyo），2021，52：101915. doi：10.1016/j.legalmed.2021.101915 .
5	GE R， PEJO E， GALLIN H， et al. The pharmacology of cyclopropyl-methoxycarbonyl metomidate： A comparison with propofol[J]. Anesth Analg，2014，118（3）：563-567. doi：10.1213/ANE.0000000000000069 .
6	WANG B， YANG J， CHEN J， et al. An etomidate analogue with less adrenocortical suppression， stable hemodynamics， and improved behavioral recovery in rats[J]. Anesth Analg，2017，125（2）：442-450. doi：10.1213/ANE.0000000000002063 .
7	PARK Y J， CHO E， KIM S H， et al. Determination of etomidate and etomidate acid in hair using liquid chromatography-tandem mass spectrometry[J]. J Forensic Sci，2022，67（6）：2479-2486. doi：10.1111/1556-4029.15113 .
8	徐若沦，解通，胡庆坤，等. 依托咪酯药理作用、药物代谢动力学及毒理学研究[J].广东公安科技，2022，30（2）：43-45.
	XU R L， XIE T， HU Q K， et al. Study of pharmacological action， pharmacokinetics and toxicology of etomidate[J]. Guangdong Gongan Keji，2022，30（2）：43-45.
9	LE MOING J P， LEVRON J C. High-performance liquid chromatographic determination of etomidate in plasma[J]. J Chromatogr，1990，529（1）：217-222. doi：10.1016/s0378-4347（00）83825-6 .
10	ELLIS E O， BECK P R. Determination of etomidate in human plasma by high-performance liquid chromatography[J]. J Chromatogr，1982，232（1）：207-211. doi：10.1016/s0378-4347（00）86028-4 .
11	JUNG Y K， YOU S Y， KIM S Y， et al. Simultaneous determination of etomidate and its major metabolite， etomidate acid， in urine using dilute and shoot liquid chromatography-tandem mass spectrometry[J]. Molecules，2019，24（24）：4459. doi：10.3390/molecules 24244459 .
12	DENG X， SIMPSON V J. Gas chromatographic-mass spectrometric determination of etomidate in mouse brain[J]. J Pharmacol Toxicol Methods，2000，43（1）：73-77. doi：10.1016/S1056-8719（00）00087-3 .
13	崔海燕，吕晨曦，师燕华，等. LC-MS/MS法测定血液中卡马西平及其代谢物[J].法医学杂志，2023，39（1）：34-39. doi：10.12116/j.issn.1004-5619.2021.310901 .
	CUI H Y， LÜ C X， SHI Y H， et al. Detection of carbamazepine and its metabolites in blood samples by LC-MS/MS[J]. Fayixue Zazhi，2023，39（1）：34-39.
14	MCINTOSH M P， RAJEWSKI R A. A simple and efficient high-performance liquid chromatographic assay for etomidate in plasma[J]. J Pharm Biomed Anal，2001，24（4）：689-694. doi：10.1016/S0731-7085（00）00471-4 .
15	中华人民共和国司法部. 法医毒物分析方法验证通则： [S].2020.
	Ministry of Justice of the People’s Republic of China. General rules for method validation in forensic toxicology： [S]. 2020.
16	向平，沈敏，卓先义. 生物样品分析方法的有效性验证[J].法医学杂志，2008，24（1）：60-65. doi：10.3969/j.issn.1004-5619.2008.01.019 .
	XIANG P， SHEN M， ZHUO X Y. How to validate a bio-analytical method[J]. Fayixue Zazhi，2008，24（1）：60-65.
17	焦台风，李亚庆，康刚，等. HPLC-MS/MS法快速测定电子烟油中58种合成大麻素[J].刑事技术，2023，48（1）：62-69. doi：10.16467/j.1008-3650.2022.0017 .
	JIAO T F， LI Y Q， KANG G， et al. 58 synthetic cannabinoids rapidly determined from electronic cigarette oil by HPLC-MS/MS[J]. Xingshi Jishu，2023，48（1）：62-69.
18	JOHNSON R D， LEWIS R J. Determination of etomidate in human postmortem fluids and tissues[R/OL]. （2009-02-01）[2023-05-17]. .

目标物	保留时间/min	母离子（m/z）	子离子（m/z）	去簇电压/V	碰撞能量/eV
依托咪酯	5.27	245.0	141.0^1）	40.0	15.5
			105.0	40.0	35.0
依托咪酯酸	3.19	217.1	95.0^1）	28.0	32.0
			105.0	28.0	33.0

目标物	保留时间/min	母离子（m/z）	子离子（m/z）	去簇电压/V	碰撞能量/eV
依托咪酯	5.27	245.0	141.0^1）	40.0	15.5
			105.0	40.0	35.0
依托咪酯酸	3.19	217.1	95.0^1）	28.0	32.0
			105.0	28.0	33.0

目标物	线性方程	线性范围/（ng·mL^-1）	相关系数（r）	LOD/（ng·mL^-1）	LOQ/（ng·mL^-1）
依托咪酯	y=8 144.8 x-2 669.4	0.5~50	0.995 0	0.2	0.5
依托咪酯酸	y=7 779 x+29 864	1~100	0.998 8	0.5	1

目标物	线性方程	线性范围/（ng·mL^-1）	相关系数（r）	LOD/（ng·mL^-1）	LOQ/（ng·mL^-1）
依托咪酯	y=8 144.8 x-2 669.4	0.5~50	0.995 0	0.2	0.5
依托咪酯酸	y=7 779 x+29 864	1~100	0.998 8	0.5	1

目标物	质量浓度/（ng·mL^-1）	基质效应	回收率	冻融稳定性	长期稳定性
目标物	质量浓度/（ng·mL^-1）	基质效应	回收率	冻融稳定性	7 d	14 d	28 d
依托咪酯	0.5	18.47	96.64	110.23	103.51	110.65	91.26
	5	7.29	93.07	102.34	100.26	97.12	89.84
	50	5.42	84.25	98.49	99.55	97.24	90.75
依托咪酯酸	1	8.29	107.43	91.77	101.91	90.68	105.79
	10	7.11	110.26	102.31	96.36	93.80	92.16
	100	10.73	97.82	103.68	100.43	94.01	88.23